Gilead Exercises Option To License Nurix's Protein Degrader Molecule NX-0479
(RTTNews) - Biopharmaceutical companies Gilead Sciences, Inc. (GILD) and Nurix Therapeutics, Inc. (NRIX) announced Monday that Gilead has exercised its option to exclusively license Nurix's investigational targeted protein degrader molecule NX-0479.
This bivalent degrader, designated GS-6791, is the first development candidate resulting from the previously announced Nurix-Gilead collaboration to discover, develop, and commercialize a pipeline of innovative targeted protein degradation therapies.
Under the terms, for the NX-0479 option that Gilead is exercising, Nurix will receive an option exercise payment of $20 million and potentially could receive up to an additional $425 million in clinical, regulatory, and commercial milestone payments, as well as up to low double-digit tiered royalties on product net sales.
GS-6791 is a potent, selective, oral IRAK4 degrader that targets both the scaffold and kinase functions of the IRAK4 protein kinase to block inflammatory responses downstream of toll-like receptors (TLR) and the pro-inflammatory IL1 cytokine family of receptors (IL1Rs).
IRAK4 degradation has potential applications in the treatment of rheumatoid arthritis (RA) and other inflammatory diseases.
Gilead Recalls COVID-19 Drug Veklury For Injection
Kite Says Tecartus Shows Prolonged OS In Adults With Refractory B-cell Acute Lymphoblastic Leukemia
Gilead Sciences Says FDA OK's Updated Label Of Biktarvy To Treat Pregnant People With HIV-1
Nurix Therapeutics Says Gilead Sciences Extends Ongoing Strategic Collaboration By Addl. Two Years
Hookipa Pharma Says Gilead Purchases Addl. 15 Mln Shares Of HOOKIPA For Total Stake Of About 19.4%
Gilead Sciences, Compugen Ink Up To $848 Mln Deal For Pre-clinical Antibody Program
Gilead Company Kite Says FDA Oks RVV Manufacturing Facility In California For Commercial Production
